Enlivex Therapeutics Ltd. cash flow to debt ratio of -1.62K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Enlivex Therapeutics Ltd.'s free cash flow has increased -20.04% from $-13.11M last year to $-10.48M, signaling increasing performance

Enlivex Therapeutics Ltd.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Enlivex Therapeutics Ltd.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.00 today, signaling strengthened financials

Enlivex Therapeutics Ltd. has a net cash position, so leverage is healthy.

Enlivex Therapeutics Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.

Enlivex Therapeutics Ltd. has insufficient data to evaluate this check.

Enlivex Therapeutics Ltd.'s short-term assets of $1.74B exceed its short-term liabilities of $9.02M

Enlivex Therapeutics Ltd.'s return on assets of 53.10% is higher than the 5.00% threshold, indicating efficient asset utilization

Enlivex Therapeutics Ltd.'s return on equity of 248.08%, is higher than 15.00%, indicating good performance

Enlivex Therapeutics Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Enlivex Therapeutics Ltd. had positive net income in only 1 out of 5 years, indicating unstable earnings

Enlivex Therapeutics Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it

Enlivex Therapeutics Ltd. has negative free cash flow, indicating cash burn

Enlivex Therapeutics Ltd.'s yearly earnings has increased -8.33K% since last year from $-15.01M to $1.24B, signaling increasing performance

Enlivex Therapeutics Ltd.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -0.49% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Enlivex Therapeutics Ltd. has insufficient revenue history to calculate 3-year revenue CAGR.

Enlivex Therapeutics Ltd. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Enlivex Therapeutics Ltd. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Enlivex Therapeutics Ltd. has insufficient data to evaluate this check.

Enlivex Therapeutics Ltd. has an earnings yield of 20.29K%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Enlivex Therapeutics Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Enlivex Therapeutics Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Enlivex Therapeutics Ltd. has insufficient data to evaluate this check.

Enlivex Therapeutics Ltd. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Enlivex Therapeutics Ltd. has a price-to-book ratio of 0.00x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Enlivex Therapeutics Ltd. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue